Mizuho Analysts Give Wave Life Sciences (WVE) a $65.00 Price Target

Mizuho set a $65.00 target price on Wave Life Sciences (NASDAQ:WVE) in a report released on Thursday morning. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued research reports about the stock. BidaskClub cut shares of Wave Life Sciences from a strong-buy rating to a buy rating in a report on Friday, September 28th. HC Wainwright set a $49.00 price target on shares of Wave Life Sciences and gave the stock a buy rating in a report on Friday, August 10th. Finally, Leerink Swann began coverage on shares of Wave Life Sciences in a report on Tuesday, November 27th. They set an outperform rating and a $61.00 price target for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Wave Life Sciences has an average rating of Buy and a consensus target price of $58.20.

Shares of WVE stock opened at $47.49 on Thursday. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $1.38 billion, a P/E ratio of -12.34 and a beta of 1.09. Wave Life Sciences has a fifty-two week low of $31.65 and a fifty-two week high of $56.00.



Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Friday, November 9th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.02). The business had revenue of $4.49 million during the quarter, compared to analyst estimates of $5.36 million. Wave Life Sciences had a negative net margin of 1,114.49% and a negative return on equity of 112.13%. As a group, research analysts predict that Wave Life Sciences will post -5 EPS for the current year.

In other news, VP Chandra Vargeese sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $55.00, for a total transaction of $165,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gregory L. Verdine sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $38.86, for a total transaction of $582,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 59,075 shares of company stock valued at $3,018,600 in the last quarter. 44.20% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in Wave Life Sciences by 5,257.8% in the 2nd quarter. Wells Fargo & Company MN now owns 360,633 shares of the company’s stock valued at $13,794,000 after purchasing an additional 353,902 shares during the last quarter. BlackRock Inc. raised its position in Wave Life Sciences by 37.0% in the 2nd quarter. BlackRock Inc. now owns 1,201,655 shares of the company’s stock valued at $45,963,000 after purchasing an additional 324,659 shares during the last quarter. Point72 Asset Management L.P. raised its position in Wave Life Sciences by 727.4% in the 2nd quarter. Point72 Asset Management L.P. now owns 350,000 shares of the company’s stock valued at $13,388,000 after purchasing an additional 307,700 shares during the last quarter. BB Biotech AG raised its position in Wave Life Sciences by 21.7% in the 3rd quarter. BB Biotech AG now owns 1,385,002 shares of the company’s stock valued at $69,250,000 after purchasing an additional 247,117 shares during the last quarter. Finally, Boxer Capital LLC raised its position in Wave Life Sciences by 17.8% in the 2nd quarter. Boxer Capital LLC now owns 1,590,600 shares of the company’s stock valued at $60,840,000 after purchasing an additional 240,600 shares during the last quarter. Institutional investors and hedge funds own 80.78% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

See Also: Preferred Stock

Analyst Recommendations for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply